Early activation of the cardiac CX3CL1/CX3CR1 axis delays β-adrenergic-induced heart failure
Authors:
Open Access
- 9 September 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-16
Abstract
We recently highlighted a novel potential protective paracrine role of cardiac myeloid CD11b/c cells improving resistance of adult hypertrophied cardiomyocytes to oxidative stress and potentially delaying evolution towards heart failure (HF) in response to early β-adrenergic stimulation. Here we characterized macrophages (Mφ) in hearts early infused with isoproterenol as compared to control and failing hearts and evaluated the role of upregulated CX3CL1 in cardiac remodeling. Flow cytometry, immunohistology and Mφ-depletion experiments evidenced a transient increase in Mφ number in isoproterenol-infused hearts, proportional to early concentric hypertrophy (ECH) remodeling and limiting HF. Combining transcriptomic and secretomic approaches we characterized Mφ-enriched CD45+ cells from ECH hearts as CX3CL1- and TNFα-secreting cells. In-vivo experiments, using intramyocardial injection in ECH hearts of either Cx3cl1 or Cx3cr1 siRNA, or Cx3cr1−/− knockout mice, identified the CX3CL1/CX3CR1 axis as a protective pathway delaying transition to HF. In-vitro results showed that CX3CL1 not only enhanced ECH Mφ proliferation and expansion but also supported adult cardiomyocyte hypertrophy via a synergistic action with TNFα. Our data underscore the in-vivo transient protective role of the CX3CL1/CX3CR1 axis in ECH remodeling and suggest the participation of CX3CL1-secreting Mφ and their crosstalk with CX3CR1-expressing cardiomyocytes to delay HF.Keywords
Funding Information
- Institute of cardiometabolism and nutrition (ICAN innovative seeding project (PATRCRCMCE)
This publication has 46 references indexed in Scilit:
- Natural History of Concentric Left Ventricular Geometry in Community-Dwelling Older Adults Without Heart Failure During Seven Years of Follow-UpThe American Journal of Cardiology, 2011
- Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?☆Pharmacological Research, 2010
- The Fractalkine Receptor CX3CR1 Protects Against Liver Fibrosis by Controlling Differentiation and Survival of Infiltrating Hepatic MonocytesHepatology, 2010
- Characterization of Synergistic Induction of CX3CL1/Fractalkine by TNF-α and IFN-γ in Vascular Endothelial Cells: An Essential Role for TNF-α in Post-Transcriptional Regulation of CX3CL1The Journal of Immunology, 2010
- Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial InfarctionJACC: Cardiovascular Imaging, 2008
- Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failureJournal of Molecular and Cellular Cardiology, 2008
- Knockout of β 1 ‐ and β 2 ‐adrenoceptors attenuates pressure overload‐induced cardiac hypertrophy and fibrosisBritish Journal of Pharmacology, 2008
- Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathwayBiochemical Journal, 2003
- β-Adrenergic Activation Initiates Chamber Dilatation in Concentric HypertrophyHypertension, 2003
- Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout MiceCirculation, 2003